SciELO - Scientific Electronic Library Online

 
vol.18 número1Uso de inhibidores de la aromatasa en el tratamiento primario del cáncer de mama índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Venezolana de Oncología

versión impresa ISSN 0798-0582

Resumen

ACOSTA F, Víctor et al. Carcinoma ductal in situ. experiencia en el centro clínico de estereotaxia ceclines. Rev. venez. oncol. [online]. 2006, vol.18, n.1, pp.2-8. ISSN 0798-0582.

OBJECTIVE: Analyze feasibility of pre-operative percutaneous diagnosis and indications of sentinel node biop-sy in ductal carcinoma in situ. METHODS: Fifty cases of ductal carcinoma in situ treated from March 1997 through November 2004 were analyzed. We define pureductal carcinoma in situ as those lesions without evidence of micro-invasion; ductal carcinoma in situ with micro-invasion (ductal carcinoma in situ-mic) are those with infiltration equal or less than 2mm or 3 clusters of micro-invasion equal or less than 1mm. All had pre-operative biopsies: 41 (82 %) percutaneous and 9 (18 %) excisional. Ductal carcinoma in situ was classified according to histological patterns as solid, cribiform, micro-papillary and mixed. In 22 patients (44 %) biopsy of the sentinel node was performed (SG): 11 (50 %) cases were ductal carcinoma in situ and 11 (50 %) ductal carcinoma in situ-mic. RESULTS: Regarding percutaneous biopsies, 70.75 % were pure ductal carcinoma in situ and 29.26 % were ductal carcinoma in situ-mic. 96 % were treated with surgery with or without radiotherapy and 4 % received radiotherapy as the only treatment. Of those treated with surgery, 69.23 % were pure ductal carcinoma in situ and 30.76 % were ductal carcinoma in situ-mic. In 5 cases (12.82 %), there was a misdiagnosis of pure ductal carcinoma in situ in the biopsy, and the study of the surgical specimen revealed microinvasion. In 95.45 % of the cases the SG was identified and in 95.23 % of the cases, it was negative. There was no evidence of positive SG in cases of pure ductal carcinoma in situ. CONCLUSIONS: We recommend pre-operative percutaneous tissue diagnosis in ductal carcinoma in situ. In ductal carcinoma in situ-mic, SG biopsy should be performed.

Palabras clave : Cancer; breast; carcinoma in situ; diagnosis; sentinel node; treatment; surgery; radiotherapy.

        · resumen en Español     · texto en Español